← Leaderboards
Mustafa Khasraw
Duke University
$893,984
Attributed
$893,984
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $264.3K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$893,984 · 2
By mechanism
U19$893,984 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- David M. Ashley$7,073,119
- Oliver Michael Colvin$5,510,946
- Roger E McLendon$2,833,433
- Judith A Voynow$8,542,123
- Charles Michael Cotten$5,917,623
Others in their field
Other Emerging Leaders on “Adult Glioblastoma”
- Pier Paolo Peruzzi · Brigham And Women'S Hospital$3,941,735
- Peiwen Chen · University Of Tx Md Anderson Can Ctr$3,558,979
- Mario Luca Suva · Brigham And Women'S Hospital$3,268,993
- Krishna Pl Bhat · University Of Tx Md Anderson Can Ctr$3,026,399
- David M. Ashley · Duke University$3,020,772
- Wen Jiang · Ut Southwestern Medical Center$2,817,621
Research focus
Adult GlioblastomaEarly Phase Clinical TrialAnimalsAnti-Tumor Immune ResponseAftercareAdultBiological MarkersBiologyBlood - Brain Barrier AnatomyBrain NeoplasmsCell DeathCellsCheckpoint InhibitionBiologicalClinical TrialsCohortCollaborationsCyclic GmpCytotoxicityDeoxyguanosineDependenceDesignDna DamageEfficacy Evaluation
Grant awards (5)
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study$264,339
U19 · FY2025 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study$243,168
U19 · FY2024 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study$134,044
U19 · FY2023 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study$145,688
U19 · FY2022 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study$106,745
U19 · FY2021 · CA · contact PI